Korro Bio

Korro Bio is a biotechnology company developing RNA editing therapeutics that precisely modify single nucleotide to correct disease-causing proteins. By leveraging the body's endogenous RNA editing enzymes, the company creates programmable, single-base edits that can restore normal protein function without altering DNA. Its focus spans neurodegenerative disorders, inherited retinal diseases, and other genetic conditions where traditional gene therapy faces delivery or safety challenges. Korro Bio differentiates itself through a proprietary platform that delivers highly specific edits with minimal off-target activity, positioning it as a leader in next-generation precision medicine.